Sopharma stock edges lower as August sales stay on strong growth path

Published on 09/21/2026 at 19:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sopharma stock slipped modestly to EUR 2.50 on the Bulgarian Stock Exchange as of September 21, 2026, while sales for August 2026 rose 1 percent year on year. From January through August 2026, total sales climbed 43 percent compared to the same period of 2025, driven by export growth.

Sopharma, BG11SOSOBT18, Illustration mit AI erstellt.

Sopharma stock (ISIN BG11SOSOBT18) traded at EUR 2.50 on the Bulgarian Stock Exchange, down 0.79 percent on September 21, 2026, according to a session report from the local market.

Sales growth remains a key driver

According to MarketScreener on September 21, 2026, Sopharma reported preliminary sales data showing that revenue in August 2026 increased by 1 percent compared with August 2025.

As the same release notes, domestic sales in August 2026 fell by 3 percent year on year, while export sales rose by 4 percent versus August 2025, underlining that demand outside Bulgaria is currently offsetting the softer home market.

Year-to-date figures highlight strong exports

For the period from January through August 2026, Sopharma recorded a 43 percent increase in sales compared with the same eight-month period of 2025, according to MarketScreener.

The company indicated that year-to-date domestic sales were up 3 percent, while export sales surged by 68 percent over the same period of 2025, highlighting exports as the main growth engine for 2026 so far.

Stock reaction and investor view

Per a closing summary of the Bulgarian Stock Exchange on September 21, 2026, shares of Sopharma fell by 0.79 percent to EUR 2.50, implying a modest pullback despite the strong cumulative sales growth reported for the year.